Story perspectives

Abivax shares plunge 32% as trial sparks cancer concerns

6/2/2026

Summary

Abivax Shares Plummet

Abivax shares fell up to 32% after obefazimod trial data raised cancer concerns.
The 44-week study reported remission rates of 50.8% and 51.3% versus 10.4% for placebo.
Three patients on the 50 mg dose developed prostate cancer, breast cancer and colonic dysplasia.
Investigators said the cancers were unrelated to the drug, prompting ongoing safety debate.
The filing for Q4 2026 is expected to support sales of $5 billion per disease, according to analysts.

Summary

Abivax Files

CEO Marc de Garidel said Abivax will submit a U.S. filing for obefazimod in Q4 2026 to meet labeling needs.
Stifel analyst Damien Choplain called the malignancy signal a labeling overhang, not a safety risk, noting AbbVie’s Rinqvoc sold $8.3 billion in 2025 despite an FDA cancer warning.
The comparison implies that a similar FDA warning may still permit obefazimod’s market entry despite cancer cases.

History

Historical Context

In 2007 the FDA placed a black-box warning on GlaxoSmithKline’s diabetes drug Avandia after meta-analyses linked it to heart attacks, prompting U.S. sales that had peaked at $2.5 billion in 2006 to tumble sharply. The Avandia episode, echoing the earlier Vioxx safety scandal, illustrates how FDA warnings can reshape market prospects for new drugs such as Abivax’s obefazimod.

1 of 3

Abivax Shares Plummet

Abivax shares fell up to 32% after obefazimod trial data raised cancer concerns.
The 44-week study reported remission rates of 50.8% and 51.3% versus 10.4% for placebo.
Three patients on the 50 mg dose developed prostate cancer, breast cancer and colonic dysplasia.
Investigators said the cancers were unrelated to the drug, prompting ongoing safety debate.
The filing for Q4 2026 is expected to support sales of $5 billion per disease, according to analysts.

1 / 3